Atrial fibrillation in heart failure: A comprehensive review

American Journal of Medicine

Volumn 123, Issue 3, 2010, Pages 198-204

  Deedwania, Prakash C ^a,b   Lardizabal, Joel A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Arrhythmia; Atrial fibrillation; Cardiomyopathy; Heart failure

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEUROHORMONE;

CARDIOMYOPATHY; CATHETER ABLATION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ELECTROPHYSIOLOGY; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HEART FAILURE; HIGH RISK PATIENT; HUMAN; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; HEART FUNCTION TEST; METHODOLOGY;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; HEART FAILURE; HUMANS; PROGNOSIS;

EID: 77950481355     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.06.033     Document Type: Review

References (60)

1. Lloyd-Jones D, Larson M, Leip E, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106:3068-3072. (Pubitemid 35440290)
2. Lloyd-Jones D, Adams R, Carnethon M, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21-e181.
3. Lloyd-Jones D, Wang T, Leip E, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004; 110:1042-1046. (Pubitemid 39319000)
4. Miyasaka Y, Barnes ME, Bailey KR, et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol. 2007;49:986-992.
5. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA. 1994;271:840-844.
6. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
7. Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). Circulation. 1998;98:2574-2579. (Pubitemid 29001197)
8. Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigation of arrhythmia and mortality on dofetilide (DIAMOND) substudy. Circulation. 2001;104:292-296. (Pubitemid 32666950)
9. MERIT-HF Study group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-2007.
10. Carson PE, Johnson GR, Dunkman WB, et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87(6 Suppl):VI102-VI110. (Pubitemid 23164229)
11. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
12. De Ferrari GM, Klersy C, Ferrero P, et al; ALPHA Study Group. Atrial fibrillation in heart failure patients: prevalence in daily practice and effect on the severity of symptoms. Data from the ALPHA study registry. Eur J Heart Fail. 2007;9:502-509. (Pubitemid 46561482)
13. Solti F, Vecsey T, Kékesi V, Juhász-Nagy A. The effect of atrial dilatation on the genesis of atrial arrhythmias. Cardiovasc Res. 1989; 23:882-886. (Pubitemid 19269865)
14. Eijsbouts SC, Majidi M, van Zandvoort M, Allessie MA. Effects of acute atrial dilation on heterogeneity in conduction in the isolated rabbit heart. J Cardiovasc Electrophysiol. 2003;14:269-278. (Pubitemid 36444468)
15. Kalifa J, Jalife J, Zaitsev AV, et al. Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation. 2003;108:668-671. (Pubitemid 36999249)
16. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation. 2001;104:2608-2614. (Pubitemid 33104801)
17. Boyden PA, Tilley LP, Albala A, et al. Mechanisms for atrial arrhythmias associated with cardiomyopathy: a study of feline hearts with primary myocardial disease. Circulation. 1984;69:1036-1047. (Pubitemid 14137300)
18. Yeh Y, Wakili R, Qi X, et al. Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. Circ Arrhythm Electrophysiol. 2008;1:93-102.
19. Li D, Melnyk P, Feng J, et al. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation. 2000;101: 2631-2638. (Pubitemid 30350643)
20. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997;29:709-715. (Pubitemid 27128241)
21. Byrne MJ, Raman JS, Alferness CA, et al. An ovine model of tachycardia- induced degenerative dilated cardiomyopathy and heart failure with prolonged onset. J Card Fail. 2002;8:108-115. (Pubitemid 34521421)
22. Nerheim P, Birger-Botkin S, Piracha L, Olshansky B. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation. 2004;110:247-252. (Pubitemid 38960795)
23. Dandamudi G, Rampurwala AY, Mahenthiran J, et al. Persistent left ventricular dilatation in tachycardia-induced cardiomyopathy patients after appropriate treatment and normalization of ejection fraction. Heart Rhythm. 2008;5:1111-1114.
24. Leonard JJ, Shaver J, Thompson M. Left atrial transport function. Trans Am Clin Climatol Assoc. 1981;92:133-141.
25. Rahimtoola SH, Ehsani A, Sinno MZ, et al. Left atrial transport function in myocardial infarction. Importance of its booster pump function. Am J Med. 1975;59:686-694.
26. Raymond RJ, Lee AJ, Messineo FC, et al. Cardiac performance early after cardioversion from atrial fibrillation. Am Heart J. 1998;136:435-442. (Pubitemid 28413540)
27. Shite J, Yokota Y, Yokoyama M. Heterogeneity and time course of improvement in cardiac function after cardioversion of chronic atrial fibrillation: assessment of serial echocardiographic indices. Br Heart J. 1993;70:154-159. (Pubitemid 23248031)
28. Pardaens K, Van Cleemput J, Vanhaecke J, Fagard RH. Atrial fibrillation is associated with a lower exercise capacity in male chronic heart failure patients. Heart. 1997;78:564-568. (Pubitemid 28034204)
29. Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol. 1997;30:1039-1045. (Pubitemid 27435898)
30. Pozzoli M, Cioffi G, Traversi E, et al. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol. 1998;32:197-204. (Pubitemid 28351062)
31. Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol. 1998;32:695-703. (Pubitemid 28435256)
32. Olsson LG, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol. 2006;47:1997-2004.
33. Crijns HJ, Tjeerdsma G, de Kam PJ, et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J. 2000;21:1238-1245. (Pubitemid 30487771)
34. Swedberg K, Olsson LG, Charlesworth A, et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J. 2005;26:1303-1308. (Pubitemid 41435461)
35. Fonarow GC. A review of evidence-based beta-blockers in special populations with heart failure. Rev Cardiovasc Med. 2008;9:84-95.
36. Adams KF, Lindenfeld J, Arnold JM, et al. HFSA 2006 comprehensive heart failure practice guideline. J Card Fail. 2006;12:e1-e119.
37. Wyse DG, Waldo AL, DiMarco JP, et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-1833. (Pubitemid 35417773)
38. Van Gelder IC, Hagens VE, Bosker HA, et al; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-1840. (Pubitemid 35417774)
39. Opolski G, Torbicki A, Kosior DA, et al; Investigators of the Polish How to Treat Chronic Atrial Fibrillation Study. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest. 2004;126:476-486. (Pubitemid 39093433)
40. Carlsson J, Miketic S, Windeler J, et al; STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41:1690-1696. (Pubitemid 36584236)
41. Hagens V, Van Veldhuisen D, Camp O, et al. Effect of rate and rhythm control on left ventricle function and cardiac dimensions in patients with persistent atrial fibrillation: results from the RAte Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study. Heart Rhythm. 2005;2:19-24. (Pubitemid 40104304)
42. Shelton RJ, Clark AL, Goode K, et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart. 2009;95:924-930.
43. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667-2677. (Pubitemid 351860859)
44. Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol. 1992;20: 527-532.
45. Pratt CM, Singh SN, Al-Khalidi HR, et al. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. J Am Coll Cardiol. 2004;43:1211-1216. (Pubitemid 38452599)
46. Singh BN, Connolly SJ, Crijns HJ, et al; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-999. (Pubitemid 47367078)
47. Køber L, Torp-Pedersen C, McMurray JJ, et al; Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678-2687. (Pubitemid 351860860)
48. ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-678.
49. Gaynor SL, Schuessler RB, Bailey MS, et al. Surgical treatment of atrial fibrillation: predictors of late recurrence. J Thorac Cardiovasc Surg. 2005;129:104-111. (Pubitemid 40038102)
50. Stulak JM, Dearani JA, Daly RC, et al. Left ventricular dysfunction in atrial fibrillation: restoration of sinus rhythm by the Cox-maze procedure significantly improves systolic function and functional status. Ann Thorac Surg. 2006;82:494-500.
51. Hsu LF, Jaïs P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004;351:2373-2383.
52. Khan MN, Jaïs P, Cummings J, et al; PABA-CHF Investigators. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med. 2008;359:1778-1785.
53. Lally JA, Gnall EM, Seltzer J, Kowey PR. Non-antiarrhythmic drugs in atrial fibrillation: a review of non-antiarrhythmic agents in prevention of atrial fibrillation. J Cardiovasc Electrophysiol. 2007;18:1222-1228. (Pubitemid 47610624)
54. GISSI-HF investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1223-1230.
55. Everett TH 4th, Olgin JE. Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm. 2007;4(3 Suppl):S24-S27.
56. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832-1839. (Pubitemid 40789940)
57. ACTIVE Investigators. Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Am Heart J. 2006;151:1187-1193.
58. Cleland J, Coletta A, Yassin A, et al. Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVE-1, European CRT survey, German pre-SCD II registry, and MADIT-CRT. Eur J Heart Fail. 2009;11:1214-1219.
59. Ramaswamy K. Beta blockers improve outcome in patients with heart failure and atrial fibrillation: U.S. carvedilol study. Card Electrophysiol Rev. 2003;7:229-232. (Pubitemid 38256104)
60. Fauchier L, Grimard C, Pierre B, et al. Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure. Am J Cardiol. 2009;103:248-254.